Company


Company


Type/Product Area


Terms/Details (Month)

Abgenix Inc.

AVI BioPharma Inc.

License and option agreement; use of Abgenix's XenoMouse technology to develop fully human antibodies to human chorionic gonadotropin (hCG) for treating cancer

AVI licensed technology to generate product candidates; AVI responsible for product development, manufacturing and commercialization; Abgenix gets certain payments, milestones and royalties (1/99)

Abgenix Inc.

Genentech Inc.

New, multi-product research collaboration (supercedes agreements from 4/98 and 6/98); use of Abgenix's XenoMouse technology to generate fully human monoclonal antibodies for up to 10 antigen targets chosen by Genentech

Genentech gets rights to use technology in its research programs and option to obtain product licenses for up to 10 antigen targets, but not more than 2 in any 1 year, over 6-year term of agreement (included in the 10 are 2 targets previously identified under superceded agreements); Genentech will acquire 0.5M shares Abgenix stock for $8M; agreement can be renewed for up to 4 more targets over 3-year period; if agreement is renewed, Genentech will buy additional $2.5M in Abgenix stock at 50% premium to market; Abgenix gets $8M per target in licensing fees and milestones, making total agreement worth as much as $122.5M, plus royalties; Genentech will be responsible for product development, manufacturing and marketing (1/99)

Abgenix Inc.

Amgen Inc.

R&D collaboration under which Abgenix will use its XenoMouse technology to generate fully human monoclonal antibodies to ND antigen

Abgenix will receive an up-front research payment and could receive additional fees and milestones, plus royalties on any product sales; Amgen will be responsible for product development, manufacturing and marketing (4/99)

Abgenix Inc.

Chiron Corp.

Research license and option agreement under which Chiron will use Abgenix's XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed antigen in the field of autoimmune diseases; in a separate agreement, Chiron may use the XenoMouse to generate fully human antibodies to up to 4 cancer targets

Abgenix will receive a technology access payment and could receive additional fees and milestone payments plus royalties on future product sales (12/99)

Abgenix Inc.

CuraGen Corp.

Collaboration to develop and commercialize fully human antibody drugs using Abgenix's XenoMouse technology to generate antibodies for use in treating complex diseases, in cluding cancer and autoimmune disorders; antibodies to cancer antigens in CuraGen's database will be generated exclusively with XenoMouse technology during agreement

Abgenix will purchase $15M of CuraGen stock, and CuraGen will provide research support payments of $1.5M per year; both companies will receive reciprocating milestone and royalty payments for products resulting from the alliance (12/99)

Abgenix Inc.

Human Genome Sciences Inc.

Collaboration and technology exchange to identify dozens of human antibody drug candidates for development and commercialization; HGS gains right to use Abgenix's XenoMouse technology to generate fully human monclonal antibody drug candidates to HGS antigens

Under multi-year agreement, HGS will develop and commercialize independently antibodybased drugs arising from the collaboration; Abgenix also has an option in the future to develop and commercialize independently products derived from HGS antigens; companies will pay reciprocal milestones and royalties; in addition, Abgenix and HGS will select up to 2 targets of interest each year for shared development and commercialization (12/99)

Acadia Pharmaceuticals

Allergan

License and research collaboration agreement to discover, develop and commercialize compounds for glaucoma, based on Acadia's receptor subtype-selective muscarinic lead compounds

Acadia will grant Allergan worldwide rights to products based on Acadia's novel lead compounds for treatment of ocular disease; Acadia will provide its expertise in medicinal chemistry and highthroughput pharmacology to enable the final selection of up to two candidates for clinical development and commercialization by Allergan; Acadia may receive up to $19M for the first development candidate in the form of up-front fees, research support and traditional milestone payments; Acadia will also receive royalties on future product sales worldwide; Allergan has the right to to select a second development candidate, subject to similar milestone and royalty payments to Acadia (7/99)

Advanced Tissue
Sciences Inc.

Inamed Corp.

Development and marketing agreement for several of ATS's humanbased, tissue-engineered products for aesthetic and certain reconstructive applications

Inamed licensed rights to certain tissue-engineered products for use in cosmetic surgery, cartilage for plastic and reconstructive surgery, and extracellular matrix for use in breast reconstruction; Inamed also received an option to license rights to use extracellular matrix from ATS's 3-D culture system for softtissue augmentation; ATS could receive up to $20M in up-front and milestone payments, and from the sale of ATS common stock to Inamed at premium to market; deal also includes potential royalties for ATS (5/99)

Affymetrix Inc.

Eos Biotechnology Inc.

DNA array internal use license agreement

Eos gets nonexclusive license to certain of Affymetrix's patents to allow it to make and use its own non-light directed nucleic acid arrays for gene expression monitoring; Affymetrix gets license fee and annual royalty based on number of array-based experiments performed by Eos (2/99)

Affymetrix Inc.

Gene Logic Inc.

Use Of Affymetrix's GeneChip probe arrays to build large, commercially available gene expression database products; initially for expression patterns of 40,000 human genes and gene fragments from various normal and diseased tissues

Gene Logic will build database products and will market them broadly as resources for drug development; Gene Logic will get annual subscription fees from database users; Gene Logic will pay annual subscription fees to Affymetrix for use of GeneChip probe arrays, will purchase the probe arrays and related instrumentation and software and will pay royalties to Affymetrix on database subscription fees (1/99)

Affymetrix Inc.

deCODE Genetics Inc. (Iceland)

Use of Affymetrix's GeneChip technology for gene expression monitoring

ND (5/99)

Affymetrix Inc.

Qiagen GmbH
(subsidiary of Qiagen N.V.)

Development and commercial ization agreement for nucleic acid sample preparation solutions optimized for use with Affymetrix GeneChip arrays; agreement expands on general recommendation Affymetrix has been making for use of certain Qiagen products in expression monitoring

Non-exclusive agreement; details ND (11/99)

Algene Biotechnologies
Corp. (Canada)

Myriad Genetics Inc.

Agreement in principle for genetic research program in 3 disorders of interest to Myriad (via Algene's founder population database)

Algene will collect case samples and do genotyping in search for causal genes; Myriad will pay $5M in research funds in form of convertible debentures issued quarterly over 3 years based on research milestones; debentures have 6% annual interest and are convertible into Class B subordinate shares at market price; after 3 years, if debentures haven't been converted, Algene will repay them in cash or in exchange for acquired royalty rights; subject to execution of definitive agreement (1/99)

Algene Biotechnologies
Corp. (Canada)

Myriad Genetics Inc.

Cancellation of non-binding agreement in principle for genetic research program in 3 disorders of interest to Myriad (via Algene's founder population database)

Under original agreement, Algene would have received interest-bearing loan of C$5M from Myriad in the form of convertible deben tures (4/99)

Algene Biotechnologies
Corp. (Canada)

Genset SA
(France)

R&D agreement giving Genset exclusive access to Algene's collection of DNA samples taken from Alzheimer's sufferers, as well as a license to use Algene's genemapping results

Genset owns all intellectual property rights to results of the program; Algene will receive license fees and 1-year program funding, with milestones possible (5/99)

Alkermes Inc.

Genentech Inc.

Expansion of 1/95 collaboration for Nutropin Depot, an injectable, sustained-release formulation of Genentech's human growth hormone based on Alkermes' ProLease drug-delivery system

Terms include immediate purchase by Genentech of $35M of newly issued convertible exchangeable preferred stock of Alkermes with a conversion price of at least $45 per share; agreement includes potential milestones for Alkermes of approximately $40M; Alkermes will use preferred stock sale to fund the Nutropin Depot program and will receive payments based on sales; Genentech and its partners will be responsible for worldwide sales and marketing (4/99)

Alkermes Inc.

Targeted Genetics Corp.

Exclusive license to Alkermes' patent for the manufacture of adenoassociated viral vectors

Targeted will issue 0.5M shares of common stock as payment for upfront license fee to Alkermes for exclusive rights to issued patent and related pending patent applications; Targeted will also issue warrants to Alkermes to purchase up to 2M shares of common stock at substantial premiums to current market price for periods up to 10 years; Targeted will pay milestones and royalties on products manufactured using the technology (6/99)

Alliance Pharmaceutical
Corp.

Inhale Therapeutic Systems Inc.

Inhale acquired Alliance's PulmoSpheres particle and particle-processing technology for use in respiratory drug delivery

Alliance will receive $15M in cash and $5M in Inhale stock, plus milestones and royalties; Inhale receives rights to PulmoSpheres technology in the field of respiratory delivery, other related assets and $5M of Alliance stock (10/99)

AlphaOne Pharmaceuticals
Inc.

ProMetic Life Sciences Inc.
(Canada)

Joint venture agreement to develop alpha-1 antitrypsin

ND (4/99)

Alteon Inc.

Genentech Inc.

Termination of 12/97 development and marketing agreement on Alteon's pimagedine (for treating diabetic kidney disease) as well as 2nd-generation product

Preliminary analysis of the Phase III trial data on pimagedine in 11/98 showed that product failed to meet primary endpoint; Genentech terminated its support for the program for business reasons; Alteon regained all rights to pimagedine and any 2nd-generation products in development; Genentech will retain its equity investment in Alteon per terms of original agreement; companies remain in negotiations for a separate collaboration (2/99)

Altus Biologics Inc.
(subsidiary of Vertex Pharmaceuticals Inc.)

Vertex Pharmaceuticals Inc.

Restructuring of Vertex's investment in Altus (which it formed in 1/93 to develop and market protein stabilization technology)

Vertex will provide Altus with $3M cash in exchange for preferred stock and warrants; preferred stock gives Vertex a minority stake; Altus will operate independently going forward; Vertex retained nonexclusive, royaltyfree right to use Altus' technology for discovering, developing and manufacturing small-molecule drugs (2/99)

Ambion Inc.

Gen-Probe Inc.

License agreement; Gen-Probe will receive non-exclusive worldwide rights to use Ambion's armored RNA technology in products and processes for clinical diagnostic use

Gen-Probe will have the rights to manufacture armored RNA controls and standards for use in human diagnostic kits; further details ND (7/99)

Angstrom Pharmaceuticals

Diatide Inc.

License agreement for Angstrom's tumor-targeting technology (small cyclic peptides that bind to urokinase plasminogen activator receptor)

Diatide will have worldwide exclusive rights to imaging and certain therapeutic products, and will provide an up-front payment, research and milestone payments, and royalties on on any sales; Diatide will be responsible for clinical trials and regulatory approvals, and will also provide research support (5/99)

Aradigm Corp.

Genentech Inc.

Joint development agreement for a pulmonary delivery system for Genentech's Pulmozyme (dornase alfa) Inhalation Solution in the U.S. using Aradigm's AERx pulmonary drugdelivery technology; Pulmozyme Inhalation Solution is a recombinant human protein used in the management of cystic fibrosis (CF) to improve lung function

Aradigm will receive up-front and milestone payments during development; Genentech will provide bulk Pulmozyme to Aradigm, and Aradigm will manufacture the unit dose liquid formulations and electronic inhalers; Aradigm will be responsible for clinical development and manufacturing of the system; Genentech will be responsible for marketing and communications; there will be a mutual right of first negotiation for additional products administered by pulmonary delivery for use in CF (5/99)

Array BioPharma Inc.

Icos Corp.

Lead optimization agreement on up to 4 undisclosed targets of Icos'; Array will optimize lead chemical structures provided by Icos based on its high-speed parallel synthesis and purification technologies

Icos gets exclusive worldwide rights to develop and market any products; Icos will fund research and make milestone payments (2/99)

Array BioPharma Inc.

Neurocrine Biosciences Inc.

Research collaboration for the design and synthesis of a focused library around small molecules targeted at G-protein-coupled receptors

Array will combine its expertise in the generation of small-molecule libraries with Neurocrine computational methodology; both companies will contribute unique, proprietary chemical templates to the collaboration; financial details ND (10/99)

Array BioPharma Inc.

Tularik Inc.

License agreement for small-molecule libraries for screening against highthroughput screening assays

Tularik will gain nonexclusive access to Array's small-molecule libraries; financial details ND (8/99)

Arena Pharmaceuticals Inc.

Neurocrine Biosciences Inc.

Research collaboration; Neurocrine will apply Arena's constitutive activation technology to three of its orphan G protein-coupled receptors

ND (9/99)

ATIII LLC
(a joint venture between Genzyme Transgenics Corp. and Genzyme General)

Genzyme Molecular Oncology

Collaboration agreement in which the two companies will develop and commercialize the angiogenesis inhibitor protein aaATIII as a potential treatment for cancer

Genzyme and ATIII LLC will equally share in the development costs of the potential therapeutic, and will equally share any profits from a successful product resulting from the collaboration; ATIII LLC will have the rights to develop the therapeutic for potential non-oncologic indications (9/99)

Aurora Biosciences Corp.

Clontech Laboratories Inc.

Agreement to commercialize Aurora's mutant green fluorescent proteins (GFP; used as tag to monitor gene regulation and expression during development)

Clontech gets exclusive worldwide license to supply GFP technology to all customers (for-profit and not-forprofit) doing non-commercial research; Aurora gets up-front technology access fee and royalties (3/99)

Aurora Biosciences Corp.

Exelixis Pharmaceuticals Inc.

License agreement in which Exelixis receives certain rights to use Aurora's green fluorescent protein technology (GFP), primarily for target identification and validation

Aurora receives an up-front payment and annual fees; Exelixis may choose in the future to use Aurora's services regarding GFP screening assays for highand ultra-high-throughput screening (9/99)

Aurora Biosciences Corp.

Genentech Inc.

License agreement in which Genentech receives certain rights to use Aurora's green fluorescent protein technology (GFP) for various in vitro and in vivo applications

Aurora receives an up-front payment and annual fees, as well as milestone payments for products developed using Aurora's technology; Genentech is granted certain rights to manufacture therapeutic proteins using the GFP technology (9/99)

Avax Technologies Inc.

Neptunus International Holdings Ltd.
(Hong Kong)

Letter of agreement to form marketing joint venture for Avax's autologous cell cancer vaccine in Australia and New Zealand

Neptunus will purchase A$4M in stock and has the option to purchase up to A$10M in shares, or up to a 50% interest, in Avax's Australian subsidiary, Avax Australia Pty. Ltd.; Avax also will receive options to purchase common stock equivalent to 5% of Neptunus fully diluted shares; Avax Australia will handle R&D and marketing of the product; Neptunus has options to participate in commercialization in China, Malaysia, the Philippines and Thailand (6/99)

AVI BioPharma Inc.

SuperGen Inc.

SuperGen acquired equity interest in AVI in conjunction with 11/99 acquisition of negotiating rights in the U.S. to Avicine, AVI's therapeutic cancer vaccine in late-stage development

SuperGen acquired 7.5% of AVI's common stock in exchange for $5M in cash and stock (12/99)

AVI BioPharma Inc.

XTL Biopharmaceuticals Ltd.
(Israel)

Collaboration to evaluate and co-develop therapeutics for hepatitis B and hepatitis C; XTL will provide its TrimeraXTL animal models to test AVI's NeuGene antisense compounds against HBV and HCV

XTL will co-develop or receive royalties on compounds identified in the collaboration; further financial details ND (12/99)

Axiom Biotechnologies Inc.

Oxford Molecular Group
(UK)

Development agreement

The companies announced completion of their agreement to co-develop Axiom's Profiler '99 Cell BioInformatics solution for cell profiling and high-speed automation to create databases of cell profiles for comprehensive secondary assay applications; financial details ND (8/99)

Axon Instruments Inc.

Geron Corp.

Technology collaboration/ development of a cellular resolution, high-throughput imaging system for drug discovery

Geron joined Axon's CellPix consortium to develop imaging system for drug discovery; financial terms ND (11/99)

Axys Pharmaceuticals Inc.

Cephalon Inc.

Axys' combinatorial chemistry subsidiary, Axys Advanced Technologies Inc. (AAT), will supply diverse compound screening libraries and chemistry services for use in Cephalon's target-based assays

AAT will receive payment from Cephalon for the delivery compounds, as well as certain future payments if Cephalon uses AAT for chemistry support and services (12/99)

Axys Pharmaceuticals Inc.

PPD Inc.

Formation of joint venture company, PPGx Inc., to provide pharmacogenomics services and products

PPD's subsidiaries Intek Labs Inc. and Intek Labs Ltd. were absorbed into PPGx; PPD will provide initial funding for PPGx and gets exclusive rights to pharmacogenomics products and services; PPD paid $11M for an 18% stake in PPGx; Axys licensed to PPGx its pharmacogenomics intellectual property, bioinformatics software and Allele Frequency Database; Axys gets up-front license fee and majority ownership of PPGx; Allele Frequency Database will be available on subscription basis; PPGx initially valued at $60M (2/99)

Axys Pharmaceuticals Inc.

Protein Design Labs Inc.

Research collaboration on com pounds that interact with key cellular signaling pathways; companies will screen Axys' small-molecule library against Protein Design's selected cell-signaling pathways

Axys gets up-front payments and milestones; specific molecular targets and financial details ND (2/99)

Axys Advanced Technologies
(a subsidiary of Axys Pharmaceuticals Inc.)

Allergan

Research and development (R&D) collaboration using Axys's combinatorial chemistry technologies

Axys and Allergan entered a three-year agreement under which Axys will provide Allergan with a diverse compound screening library consisting of smallmolecule compounds created using Axys' combinatorial chemistry technologies; Axys will also provide Allergan with enabling technologies for reproducing and expanding the library chemistries; Axys will receive an up-front payment and additional payments upon product delivery and technology transfer (10/99)

Axys Advanced Technologies
(a subsidiary of Axys Pharmaceuticals Inc.)

Elitra Pharmaceuticals

Collaboration agreement in which Axys will supply diverse compound screening libraries and chemistry services for use by Elitra in proprietary target-based assays in bacteria and fungi

Axys will be paid by Elitra for the delivery of compounds, and will receive future payments if Elitra uses Axys for chemistry support and services (10/99)

Biohybrid Inc.

Micromet GmbH
(Germany)

Licensing agreement providing Micromet with exclusive rights to Biohybrid's Activating Hybrid Antibody technology patent, which covers recruitment of cytotoxic T cells from a patient to bind tumor cells using hybrid antibodies

Biohybrid receives up-front milestone and royalty payments in excess of $3M (11/99)

Bioreason Inc.

Biacore AB
(Sweden)

Instrumentation collaboration/ integrated software and biosensor assay system for ADME drug screening

Biacore made an equity investment in Bioreason; companies will share develment costs and will form a joint marketing alliance to promote the software (10/99)

Biosite Diagnostics Inc.

Corixa Corp.

Antibody development and licensing collaboration agreement

Biosite will use its Discovery Omniclonal technology to generate antibodies for Corixa's use in conducting protein target research; Biosite will receive diagnostic rights to the markers under study, development fees and, if Corixa successfully commercializes an antibody product, milestones and royalties; if Biosite successfully commercializes a diagnostic product for such markers, Corixa could receive milestones and royalties (9/99)

Caliper Technologies Inc.

Amgen Inc.

Subscription to Caliper's highthroughput screening technology access program

Amgen subscribed to technology access program and also gets access to successive generations of Caliper's LabChip nanoscale screening systems for biochemical and cellular drug targets; Caliper gets license fee, annual subscription fees, reimbursal of support costs (1/99)

Caliper Technologies Inc.

Neurocrine Biosciences Inc.

Research collaboration on drugs for treating diseases of central nervous and immune systems; development of ultra-high-throughput screening assays via Caliper's lab-on-a-chip technology to screen for lead compounds directed against targets from Neurocrine's neurogenomics research program

Companies will jointly develop at least 35 enzyme, receptor and functional cellular assays derived from Neurocrine's neurogenomics program; will screen assays against Neurocrine's chemical library and Caliper's compound collection; Caliper gets payment on delivery of screening data, milestones and royalties (1/99)

Cambridge Antibody
Technology (UK)

Human Genome Sciences

R&D agreement for the development of fully human monoclonal antibody therapeutics; Cambridge will use its high-throughput antibody isolation technologies to generate high-affinity, fully human monoclonal antibodies specific for up to three target human proteins identified by and proprietary to Human Genome Sciences

Cambridge could receive milestone and royalty payments on products and will receive research support funding (8/99)

Cambridge Neuro Science Inc.

Creative BioMolecules Inc.

Licensing agreement on Cambridge NeuroScience's rights to growth factor neurotrophic protein (GDF-1; member of transforming growth factorbeta super family) for treating nervous system disorders

Creative BioMolecules gets exclusive rights to GDF-1; Cambridge NeuroScience gets cash payment and royalties (1/99)

Cantab Pharmaceuticals plc (UK)

Celltech Therapeutics
(UK)

License agreement for the development of therapeutic antibodies to the OX40 receptor for chronic inflammatory and autoimmune disorders

Cantab granted Celltech an exclusive license to its OX40 antibody program; Cantab has a two-year option to buy into the development of products arising from the agreement; financial details ND (10/99)

Catalytica Advanced Technologies Inc.
(a subsidiary of Catalytica Inc.)

CombiChem Inc.

Joint-venture agreement combining the companies' respective proprietary and patented technologies to provide catalytic-based combinatorial discovery services to third parties in catalytic materials, and products and processes derived from these materials; the companies will form Aperion LLC, a limited liability company, to be headquartered in California

ND (6/99)

Catalytica Inc.

Nabi

U.S. distribution agreement for Catalytica's Aloprim (intravenous allopurinol) for treating elevated serum and urinary uric acid levels related to cancer therapy

Nabi will sell and Catalytica will manufacture Aloprim; both companies will share the product's profits (6/99)

Celera Genomics

Amgen Inc.

Subscription to 3 of Celera's database products: Human Gene Index, Drosophila Genome Database and the Human Genome Database

5-year agreement; Amgen gets subscription to databases and early access to new genomic information; Amgen retains all rights to any discoveries it makes to use in drug development programs; Amgen will also provide input into development of Celera's products; Celera will focus on gene discovery; Amgen responsible for product development and commercialization; Celera gets milestones and royalties (1/99)

Celera Genomics

Gemini Research Ltd.
(a subsidiary of Gemini Holdings plc)

R&D collaboration to discover genes and genetic polymorphisms associated with common, chronic, age-related diseases; the collaboration will combine Gemini's clinical genetics approach with Celera's DNA sequence information and computational gene discovery capability

Celera and Gemini will commercialize the jointly owned results by jointly licensing the rights to discoveries to third parties; both parties will share in the revenues received from licensing fees, milestone payments and royalties arising from the collaboration (9/99)

Cell Genesys Inc.

EntreMed Inc.

Research collaboration to evaluate gene therapy for cancer; EntreMed's Angiostatin and Endostatin proteins will be combined with Cell Genesys' adenoviral and adeno-associated viral gene delivery systems

The two companies will consider a potential business relationship based on the results of the studies performed under this collaboration; financial details ND (8/99)

Cell Genesys Inc.

Rigel Pharmaceuticals Inc.

Research collaboration and license agreement

Rigel will employ its proprietary functional genomics technology to identify novel therapeutic genes for the treatment of cancer, and Cell Genesys will be granted exclusive, worldwide rights to these genes in the field of gene therapy; Rigel will gain access to certain Cell Genesys patents and technology pertaining to retroviral gene delivery technology; financial details ND (9/99)

CellMart Inc.

Neocrin Co.

Option for a license to CellMart's technology for expanding human islet cells for the diagnosis, prevention and treatment of diabetes

Neocrin acquired option for worldwide license; further details ND (6/99)

Cellomics Inc.

Molecular Probes Inc.

Agreement gives Cellomics rights to key MPI fluorescence technologies and products for use in Cellomics' reagents, assays and kits for High Content Screening applications

Cellomics gains exclusive rights to incorporate aspects of MPI's technology into High Content Screening system, plus non-exclusive rights to certain MPI technology for reagents, assays and kits used in high-throughput screening (4/99)

Cellomics Inc.

ACLARA BioSciences Inc.

Agreement to develop, manufacture and market the CellChip System for advanced whole-cell analyses in the life science markets; collaboration combines ACLARA's expertise in microfluidics and microfabrication with Cellomics' skills in cell and molecular biology, fluorescence-based reagents, optical detection, informatics and cell patterning strengths

Companies will seek additional corporate partners to complete the system; additional financial details ND (11/99)

Cellomics Inc.

Schenley Park Research Inc.

Collaboration to develop new analytical software products for data mining of life sciences research; Schenley's data-mining expertise will bolster Cellomics' program to create a systematic knowledge base of the cell

Cellomics has an option to license certain data-mining tools exclusively for cell analysis in life sciences applications; further financial details ND (11/99)

Cellular Genomics Inc.

Oxford GlycoSciences
(UK)

R&D collaboration focused on applying proteome analysis to the discovery of novel proteins and their associated genes involved in key processes in immune system modulation

Cellular Genomics and Oxford will jointly pursue a program that includes exclusive access to Cellular's dendritic cell and T-cell populations; proteome mapping and analysis will be carried out by Oxford; financial details ND (9/99)

Centeon LLC

Principia Pharmaceutical Corp.

License agreement for Centeon's recombinant albumin fusion proteins and related yeast production technology for the treatment of cancer, viral diseases and growth deficiencies

Centeon will grant Principia exclusive, worldwide rights to recombinant albumin fusion proteins and related yeast production technology; Centeon will receive milestone payments, royalties, license fees and an equity position in Principia; Centeon will retain rights to fusion proteins within its core plasma protein business and in other areas (8/99)

Cerep SA
(France)

Tibotec NV
(Belgium)

Research collaboration to discover new drug candidates for HIV; Tibotec will screen Cerep's compound library for potential leads; companies will jointly undertake profiling, lead optimization and preclinical testing

Companies will share costs and revenues, with separate agreements to be signed for lead candidates selected for further development (6/99)

ChemDiv Inc. and Contract Services Co. subsidiary

Nanoscale Combinatorial Synthesis Inc.

ChemDiv will provide chemical intermediates for synthesis of custom libraries for Nanoscale customers, and CSC will provide scale-up capabilities

ND (4/99)

ChiRhoClin Inc.

Repligen Corp.

License agreement for in vivo diagnostic products based on the hormone secretin

Repligen will receive exclusive rights to two in vivo products based on the hormone secretin; Repligen will be responsible for product marketing and distribution following approval by the FDA, and will pay ChiRhoClin an up-front payment, development milestones and a royalty based on sales; ChiRhoClin will be responsible for regulatory affairs and manufacturing (10/99)

Chiron Corp.

Biomira Inc.
(Canada)

Revision of collaboration agreement; Biomira will reacquire all rights held by by Chiron to Theratope vaccine in order to involve a third party in the development and commercialization of the vaccine

Chiron will receive an undisclosed amount from Biomira to retain an ongoing interest in the development and commercialization of Theratope; the agreement is structured as a series of put and call options between the two companies, and may be modified over time (9/99)

Chiron Corp.

Gilead Sciences Inc.

Settlement of patent suit under which Gilead admits infringement of Chiron's U.S. hepatitis C virus protease patents

Gilead made a lump-sum payment to Chiron, admitted infringement and assigned to Chiron a co-ownership interest to all of Gilead's HCV protease inhibitor research results; as a result of declining a license, Gilead also agreed to cease screening for HCV protease inhibitors and to provide Chiron limited ongoing support in Chiron's similar inhibitor research (12/99)

Chromagen Inc.

CombiChem Inc.

Assay development and drug-screening agreement under which Chromagen will develop biological assays and screen CombiChem compounds for multiple targets pursued by CombiChem in its internal drug-discovery program

Chromagen will receive research support and a percentage of future payments received by CombiChem upon outlicensing of drug candidates to pharmaceutical companies (3/99)

Clontech Laboratories Inc.

Progen Industries Ltd.
(Australia)

Distribution agreement on Clontech's life science products for genetic engineering research

Progen will be exclusive distributor of products in Australia (1/99)

CombiChem Inc.

ICOS Corp.

Expansion of 4/98 drug-discovery and development collaboration with addition of ND target discovered by ICOS; CombiChem will utilize its Discovery Engine, an iterative approach combining software for hypothesis generation, a computerbased virtual library and rapid synthesis capability

ICOS has exclusive worldwide rights to develop and market any products arising from collaboration; under new agreement CombiChem is to receive an up-front payment, research support, and milestone and royalty payments for any products arising from work on the new target (5/99)

Connetics Corp.

Soltec Research Pty Ltd.
(a subsidiary of F.H. Faulding & Co. Ltd.; Australia)

Connetics licensed certain applications of Soltec's topical delivery technologies, including aerosol foam formulations and Soltec's Liquipatch technology; focus is on dermatological indications

Connetics will pay Soltec $1M in cash and stock, in addition to milestone, development and royalty payments (12/99)

Connetics Corp. and Xoma LLC

The Immune Response Corp.

Connetics and Xoma will assign their T-cell receptor intel lectual property to Immune Response, which owns additional TCR technology and will carry forward development of products for chronic connective tissue and autoimmune diseases

Connetics and Xoma will each receive a cash payment, stock in Immune Response and royalties on future sales; Arthur Vandenbark, one of the inventors, will also receive royalties (12/99)

Corixa Corp.

Idec Pharmaceuticals Corp.

Research collaboration; use of genes identified by Corixa that are selectively expressed in prostate cancer as targets for monoclonal antibody-based therapies

Idec will develop monoclonal antibodies that can be used as monotherapy or in conjunction with radiolabeled yttrium; further details ND (2/99)

Corixa Corp.

Introgen Therapeutics Inc.

License agreement; Corixa granted Introgen an exclusive worldwide license to the patented universal tumor suppressor gene, mda7, for use in gene therapy

Corixa will receive an up-front license fee, as well as undisclosed milestone payments, research and development payments and royalties on potential product sales (8/99)

Corvas International Inc.

Vascular Genomics Inc.

Termination of option agreement

Corvas will not exercise its option, acquired in 1997, to purchase Vascular Genomics; upon expiration or cancelation of the option, Vascular stockholders have a right to put 19.9% of Vascular stock to Corvas for a purchase price of $3.9M ($3 per share); instead, Corvas will issue the stockholders a total of 0.25M shares of common stock and an undisclosed amount of cash (7/99)

CuraGen Corp.

COR Therapeutics Inc.

Product-discovery and pharmacogenomics agreement under which CuraGen will apply its SeqCalling, GeneCalling and PathCalling technologies, related services and pharmacogenomics expertise to identify drug targets and develop cardiovascular drugs

CuraGen retains rights to newly discovered protein therapeutics for use in the company's internal drug-development programs, while COR retains the rights to small-molecule and inhibitory antibody therapeutics emanating from this agreement; renewable collaboration is valued at $2.6M for initial period of 18 months; CuraGen may also receive milestone and royalty payments for products developed by COR as a result of collaboration (5/99)

CV Therapeutics Inc.

Innovex
(unit of Quintiles Transnational Corp.)

U.S. marketing and sales agreement for CV's ranolazine, currently in Phase III trials for chronic stable angina

Quintiles will invest $5M in CV's common stock, and upon FDA's acceptance of ranolazine NDA will make available up to a $10M secured credit facility for funding of pre-launch activities to be performed by Innovex under a traditional fee-for-service agreement; the credit facility is convertible into CV common stock at the election of Quintiles under certain circumstances; Quintiles will also make a milestone payment of $10M upon product launch, which can be offset by the loan; Innovex will conduct pre-launch activities, hire and train a cardiology sales force for the product, and provide post-launch marketing and sales; Innovex will provide services for at least 3 years after launch, and for years 4 and 5 if sales goals are met; 1st-year fee expected to be at least $19M (5/99)

Desmos Inc.

TheraCyte Inc.

Research collaboration in which the two companies will explore their combined technologies as a potential treatment for insulin-dependent diabetics

Desmos will provide pancreatic islets using its expansion and differentiation technologies; TheraCyte will provide the immunoprotective barrier using its encapsulation technology; financial details ND (8/99)

Digital Gene Technologies Inc.

Immunex Corp.

Immunex renewed experimentation license on a Digital Gene gene implicated in inflammatory bowel disease; molecule is the 1st of 6 licensed by Immunex during the 1st year of research collaboration using Digital Gene's TOGA gene expression technology to discover diagnostics and therapeutics for the treatment of inflammatory diseases of the gastrointestinal system

Agreement calls for annual renewal rights and fee payment for experimentation licenses issued for each gene chosen by Immunex (6/99)

Diversa Corp.

TerraGen Discovery Inc.

Cross-licensing agreement for patents covering methods to discover biomolecules of interest

TerraGen obtains a non-exclusive license to Diversa's patents for smallmolecule applications; Diversa pays fees to TerraGen for a co-exclusive license to specific TerraGen patents for all fields of use, outside of smallmolecule pharmaceutical applications (12/99)

Dynavax Technologies Corp.

StallergTnes S.A.
(France)

Agreement to develop treatments for seasonal allergies in Europe using Dynavax's immunostimulatory oligonucleotide sequences (ISS); initial focus is on clinical development of AIC, a highly purified form of the main ragweed allergen linked to multiple ISS

StallergTnes will have the option to acquire European marketing rights to Dynavax's ISS linked to allergens for treatment of seasonal allergies, in return for equity investments, research and development funding, and milestone and royalty payments; each company will take the lead on development of ISS/allergen conjugates for regionally specific conditions (11/99)

Endovasc Ltd.

Hermes Biosciences Inc.

Development agreement in which the two companies will co-develop a liposomal encapsulation of the vascular growth protein VEGF

ND (8/99)

EntreMed Inc.

CalbiochemNovabiochem Corp.
(unit of CN Biosciences Inc.)

Non-exclusive, worldwide license agreement

Calbiochem will receive the right to sell research-grade Endostatin and Angiostatin proteins for non-commercial research purposes, as well as researchgrade human recombinant Endostatin protein produced by EntreMed; EntreMed will receive royalty payments on all sales of both murine (mouse) and human Endostatin and Angiostatin (6/99)

EnzyMed Inc.

IntraBiotics Pharmaceuticals Inc.

Research collaboration agreement; EnzyMed will focus on lead optimization of selected IntraBiotics compounds for treatment and prevention of infectious diseases

EnzyMed will receive up-front funding and potential milestone and royalty payments (5/99)

Eos Biotechnology Inc.

Vysis Inc.

Research collaboration to validate new genomics-derived breast cancer markers; Eos will contribute targets and Vysis will validate them using fluorescence in situ hybridization technology

Vysis receives worldwide diagnostic rights, Eos therapeutic rights (6/99)

Evotec Analytical Systems GmbH
(subsidiary of Evotec BioSystems AG; Germany)

Qiagen NV
(the Netherlands)

Joint venture agreement for development and commercialization of high-throughput nucleic acid detection and purification systems; Qiagen contributes technology in nucleic acid handling, separation, purification and amplification; Evotec provides single molecule detection ability and other technology

Equally funded joint venture; Qiagen will handle worldwide distribution; further details ND (5/99)

Galileo Genomics (Canada)

Myriad Genetics Inc.

Strategic collaboration in which Myriad will receive access to DNA samples from patients in the French-Canadian population of Quebec

Myriad will acquire a 15% ownership in Galileo through a $0.75M equity investment, and will fund research at Galileo; Myriad has reserved a right of first refusal on DNA samples associated with diseases of potential interest; Myriad will receive exclusive worldwide diagnostic and therapeutic rights for all genes discovered during the collaboration, returning a royalty on any product sales based on these genes to Galileo (9/99)

Geneka Biotechnology Inc.
(Canada)

Nova Molecular Inc.
(Canada)

Collaboration agreement for functional gene expression studies into central nervous system diseases; companies will use Geneka's gene expression platform to identify transscriptional factors involved in NMI's lead therapeutic compound and related target pathways

Terms ND (11/9)

Genentech Inc.

Immunex Inc.

Licensing agreement covering Genentech's p75TNRF:Fc fusion proteins, including Immunex's FDA-approved Enbrel

Immunex will pay Genentech an initial license fee and royalties on sales of Enbrel from the date of product launch and continuing for the life of the Genentech patents (6/99)

Genentech Inc.

Immunex Inc.

Joint development and commercialization agreement for TRAIL/ Apo2L (TNF-related, apoptosisinducing ligand); companies had separately been working on diff erent forms as anticancer agents

Companies will form joint steering committee and project committee to select a single lead molecule for development, manage the development process, and allocate clinical, manufacturing and marketing responsibilities to each company (6/99)

Genome Therapeutics Corp.

Biogen Inc.

Sequencing contract under which Genome will use its sequencing techniques, automation, bioinformatics and quality control procedures to generate sequence information in support of research projects at Biogen

ND (9/99)

Genomica Corp.

Biognosis U.S. Inc.

Licensing agreement; Biognosis will use Genomica's Discovery Manager software to manage genetic analysis tasks in the course of its psychiatric phenotyping research

ND (7/99)

Genomica Corp.

Clingenix Inc.
(formerly GeneAsia Inc.)

Licensing agreement; Clingenix will use Genomica's Discovery Manager software to enhance its gene discovery research

ND (9/99)

Genomica Corp.

Orchid Biocomputer Inc.

Licensing agreement; Orchid will use Genomica's Discovery Manager software with its pharmacogenetics and Genotyping Center of Excellence to increase the speed and efficiency of its genetic bit analysis technology developed to analyze single nucleotide polymorphisms

ND (9/99)

Genovo Inc.

Genzyme General

Collaboration agreement to develop gene therapy products for lysosomal storage disorders using Genovo's proprietary viral vectors

Genovo will conduct research and development activities to develop one gene therapy product through the successful completion of a Phase I trial; Genzyme subsequently will have the option to pursue further development of that product, and to develop additional gene therapy products, in collaboration with Genovo or on its own; Genzyme has been granted an exclusive, worldwide license to all of Genovo's vector patents and technology for use in developing and commercializing gene therapy products for lysosomal storage disorders; Genovo will receive product development milestone payments and royalties on product sales; Genzyme will also make an equity investment in Genovo, and has the option to make additional equity investments (8/99)

GenVec Inc.

Cantab Pharmaceuticals plc

Cantab acquires exclusive option to license GenVec patents related to gene therapy delivery using herpes simplex virus; technology may prove useful to development of gene therapy approaches to neurological disorders

In return for an exclusive multiyear option for commercial licenses to GenVec's HSV patent portfolio, Cantab paid a signing fee and will make additional maintenance payments over the option period; to exercise an option in any disease area, Cantab will pay GenVec a commercial license fee, milestones and royalties on any sales (12/99)

Genzyme Molecular Oncology

Hybridon Inc.

License agreement; Hybridon receives a non-exclusive license to patent rights relating to antisense compounds that interfere with the cancer-related protein MDM2, methods for treating cancers with these compounds, and methods for identifying such compounds; these patent rights are exclusively licensed to Genzyme by Johns Hopkins University

In exchange for the patent rights, Genzyme receives an up-front payment; if Hybridon successfully develops therapeutic products through the use of these rights, Genzyme could receive milestone payments and royalties on product sales (9/99)

Genzyme Transgenics Corp.

Lonza Biologics
(unit of Algroup; Switzerland)

Agreement to develop purification and production methods for therapeutic proteins, including monoclonal antibodies; deal provides Genzyme Transgenics access to Lonza's infrastructure for downstream protein purification; initial projects will focus on large-scale purification of transgenic proteins and monoclonal antibodies under development at Genzyme Transgenics

Based on achievement of certain goals, Algroup will make a “significant“ investment in Genzyme Transgenics' common stock; further terms ND (5/99)

Genzyme Transgenics Corp.

Millennium BioTherapeutics Inc.
(majority-owned subsidiary of Millennium Pharmaceuticals Inc.)

R&D agreement to use Genzyme Transgenics' expertise in development of transgenically produced biotherapeutics to develop ND Millennium proteins and antibodies

ND (3/99)

Geron Corp.

Clontech Laboratories Inc.

Clontech will manufacture and market Geron's telomerase-immortalized cell lines to the not-for-profit research market; Clontech will also supply to the biotech and pharmaceutical products industries under licenses to be executed between Geron and the individual companies

Clontech will pay an up-front technology licensing fee, and the companies will share equally operating profits generated from the sale of the cell lines; Clontech will be responsible for manufacturing (3/99)

Gilead Sciences Inc.

Medarex Inc.

Development agreement; Medarex obtained an exclusive sublicense from Gilead to the CTLA-4 Blockade intellectual property rights owned by the University of California, Berkeley, to pursue methods of blocking CTLA-4

Under the terms of the agreement, Medarex also has an option to pursue certain other non-antibody-based methods of blocking CTLA-4; further details ND (8/99)

GPC AG
(Germany)

Novalon Pharmaceutical Corp.

Drug discovery collaboration for the development of a new generation of broad-spectrum antibiotics, based on a novel class of genomics-derived targets

GPC will provide Novalon with novel antibacterial targets that have been identified and validated using GPC's integrated second-generation genomics technologies; Novalon will develop highthroughput screening assays, based on its BioKey assay technology, to screen small-molecule compound libraries and identify lead compounds with antibacterial activity; on successful completion of the collaboration, the companies may enter into a broader alliance for additional targets from GPC's internal antibacterial research program; financial details ND (9/99)

ICAgen Inc.

Incyte Pharmaceuticals Inc.

Research collaboration to create ion-channel gene expression microarray (GEM)

Companies will jointly mine Incyte's LifeSeq gene sequence and expression database as well as public domain databases to identify all known ion channels; companies will also study ion-channel expression in normal and diseased tissues; ICAgen gets period of exclusive access to ion channel GEM data; Incyte will make available to its database partners the ion channel GEM as well as use it for internal R&D programs (2/99)

Iconix Pharmaceuticals Inc.

Metabolex Inc.

R&D collaboration focused on target validation and small-molecule drug discovery for genes believed to influence diabetes

Iconix will apply its proprietary assay platform and chemical diversity library to identify small-molecule modulators of potential diabetes-related genes identified by Metabolex; further details ND (8/9)

ID Vaccine
(subsidiary of ID Biomedical Corp.; Canada)

Biomira Inc.
(Canada)

Contract manufacturing for ID Vaccine's therapeutic subunit vaccine for AIDS (contains 8 different HIV-1 peptides)

Biomira will manufacture vaccine; ID Biomedical will complete all requirements to proceed with human clinical trials (1/99)

ID Vaccine
(subsidiary of ID Biomedical Corp.; Canada)

Ribi ImmunoChem Research Inc.

ID Vaccine will test Ribi's adjuvant and vaccine delivery technology in its vaccines for enterohemorrhagic Escherichia coli infection and enteropathogenic E. coli infection (intranasal delivery)

ND (2/99)

Igen International Inc.

Biogen Inc.

Product agreement in which Biogen will use Igen's M-Series high-throughput screening system for its drug discovery and development programs

ND (7/99)

Ilex Oncology Inc.

Impath Inc.

Collaboration agreement under which Impath will provide anatomic and molecular pathology services for Ilex, with the intent of creating state-of-theart services to advance international drug development

Impath made a $5M equity investment in Ilex via a private placement of preferred stock; further details ND (9/99)

ImmGenics Pharmaceuticals Inc.
(Canada)

Genzyme Corp.

Co-development agreement in which ImmGenics will work with Genzyme, using its SLAM technology to develop a high-affinity biotherapeutic monoclonal antibody to an undisclosed antigen target

ND (9/99)

Incyte Pharmaceuticals Inc.

Genentech Inc.

Expansion and extension of 1/97 genomic database partnership; the expanded agreement provides Genentech access to Incyte's LifeSeq Gold assembled database, and includes a partnering program in bioinformatics

Incyte could receive future milestone payments and royalties on sales of products developed with its technology and database information; financial details ND (7/99)

Incyte Pharmaceuticals Inc.

Millennium Pharmaceuticals Inc.

Genomic database partnership whereby Millennum will gain access to Incyte's LifeSeq Gold assembled database, as well as Incyte's LifeTools data management software

Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information; financial details ND (10/99)

Infigen Inc.

Imutran Ltd.
(UK; subsidiary of Novartis Pharma AG; Switzerland)

Strategic partnership to develop technologies for porcine gene targeting and nuclear transfer for use in xenotransplantation; use of Infigen's technology to modify DNA of pig cells

Imutran will pay up-front license fee for exclusive rights to Infigen's technology; Infigen gets guaranteed R&D funding, as well as milestones and royalties (1/99)

Inhale Therapeutics Systems Inc.

Biogen Inc.

Research collaboration and license agreement; use of Inhale's deep-lung pulmonary delivery system to deliver Avonex (recombinant interferon beta-1a) for treating multiple sclerosis

Inhale gets up-front signing fee, $25M in R&D funding and milestones, plus royalties; Biogen will provide bulk drug to Inhale for formulation into dry powder; Inhale will manufacture and package drug and supply inhalation devices; Biogen responsible for clinical development, marketing and commercialization (2/99)

Inspire Pharmaceuticals Inc.

Genentech Inc.

Collaboration to develop treatments for respiratory disorders including small molecules for cystic fibrosis and chronic bronchitis; research focuses on Inspire's inhaled P2Y2 agonists and expertise in pulmonary hydration and clearance mechanisms

Inspire could receive $78M, including $10M in cash and equity up front, milestones, and potential royalties on net sales; in the U.S., Inspire will lead early development of small molecule for CF and retains co-development and co-promotion rights in exchange for profitsharing (12/99)

Integra LifeSciences Corp.

Genetics Institute Inc.
(wholly owned subsidiary of American Home Products Corp.)

Extension of 1994 supply agreement on Integra's absorbable collagen sponges for use in Genetics Institute's bone regeneration implants (which contain recombinant human bone morphogenic protein-2)

Companies extended agreement for 5 years, through 2004 (1/99)

Introgene BV
(the Netherlands)

Tibotec NV
(Belgium)

Agreement to form Galapagos Genomics NV, a high-throughput functional genomics company focused on identification of human gene function using IntroGene's adenoviral technology in combination with Tibotec's high-throughput screening capabilities

Galapagos will be equally funded by IntroGene and Tibotec (4/99)

Invitrogen Corp.

Diversa Corp.

Exclusive license and access agreement to exchange proprietary technologies and products in specified fields of use

Diversa will receive an exclusive license to use Invitrogen's TOPO Cloning technology in Diversa's proprietary field of cloning nucleic acids from mixed populations and uncultured organisms; Invitrogen will receive exclusive access to selected proprietary DNA-modifying enzymes for use in the research reagent marketplace (3/99)

IriSys Research & Development LLC

Avanir Pharmaceuticals

Letter of intent to license IriSys' drug for treating emotional lability associated with amyotrophic lateral sclerosis, certain types of neuropathic pain and chronic cough; drug is combination of dextromethorphin and an enzyme inhibitor

Avanir gets worldwide rights to drug; IriSys gets milestone payments in cash or Avanir stock, as well as royalties (2/99)

Irori
(subsidiary of Discovery Partners International)

Ontogen Corp.

Licensing agreement on Ontogen's two patents relating to radiofrequency (RF) tagging of chemical combinatorial synthesis libraries

Irori gets exclusive rights to patents; Ontogen retains rights to use technologies internally; financial terms ND (1/99)

Irori
(a subsidiary of Discovery Partners International)

Afferent Systems Inc.

Collaboration agreement to define and develop future chemical synthesis and informatics technology and products using an interface developed by Afferent that links its software to Irori's solid phase synthesis products

Irori will begin immediate distribution of Afferent software products; financial terms ND (5/99)

Ixsys Inc.

MedImmune Inc.

Ixsys will use its directed evolution and protein engineering technologies to optimize 3 target antibodies provided by MedImmune; also, collaboration on Ixsys' humanized monoclonal antibody Vitaxin (anti-angiogenic; currently in Phase II trials for cancer)

Ixsys will optimize antibodies; MedImmune will be responsible for clinical development, manufacturing and commercialization; MedImmune will make $6.4M equity investment in Ixsys, fund research and pay milestones and royalties; total value to Ixsys of $50M (not including royalties) (2/99)

Lexicon Genetics Inc.

Cephalon Inc.

Research agreement under which Lexicon will make custom knockout mice for Cephalon using methods of homologous recombination

ND (5/99)

Lexicon Genetics Inc.

Avatar BioSci Inc.

Research agreement; Lexicon will sublicense to Avatar a segment of its Gene Trapping Vector Technology for the discovery of new drug targets in the areas of infectious diseases and cancer

Lexicon will receive an equity position of convertible preferred stock in Avatar, as well as two five-year warrants to purchase additional equity; Lexicon is also eligible for downstream rights from products developed and commercialized using its Gene Trapping technology (9/99)

Lexicon Genetics Inc.

Millennium Pharmaceuticals Inc.

Collaboration agreement; Lexicon will use its portfolio of homologous recombination technologies to create genetically engineered mice for use by Millennium in the validation of potential drug targets identified and selected by Millennium

Lexicon will generate a significant number of mice for Millennium over a three-year period; Millennium will select specified minimum numbers of mice during each year of the collaboration; financial terms ND (7/99)

Lexicon Genetics Inc.

Millennum Pharmaceuticals Inc.

Research agreement; Millennium and its affiliates will have access to Lexicon's Human Gene Trap and OmniBank databases for the discovery and development of drugs and diagnostic products

Lexicon will receive annual access fees, and may receive license fees, milestone payments and royalties on sales of drugs and diagnostic products developed with its technology and database information; (10/99)

Lexicon Genetics Inc.

Ligand Pharmaceuticals Inc.

Ligand gains non-exclusive sublicense to “positive-negative selection“ technology for generating cell lines useful to drug discovery

Ligand gains non-exclusive rights to use the technology under a sublicense; financial details ND (11/99)

LifeTime Pharmaceuticals Inc.

Dovetail Technologies Inc.

License agreement and right-offirst refusal/R&D agreement covering all Dovetail compounds, including lead compound, Beta LT, an anticancer drug and immunesystem booster in Phase I/II trials

Dovetail will continue preclinical development of 6 classes of compounds in return for milestones, and has guaranteed supplies of Beta LT for trials and future sales; additional terms ND (6/99)

LigoCyte Pharmaceuticals Inc.

Corixa Corp.

License and research agreement; Corixa will use Candida technology for the development of therapeutic and vaccine products that target infections arising from Candida albicans

LigoCyte will receive equity funding, license fees, research funding and milestone payments based on successful clinical and commercial progress, as well as a royalty on future product sales; further financial details ND (10/99)

Lion
Bioscience AG
(Germany)

Paracel Inc.

Purchase agreement; Lion will use Paracel's GeneMatcher genetic data analysis system as part of its effort to identify target genes

ND (5/99)

Lynx Therapeutics Inc.

Oxagen Ltd.

Research agreement under which Lynx will apply its technologies for extracting and genotyping single nucleotide polymorphisms (SNPs) to identify disease-associated SNPs from populations of patients with inflammatory bowel disease; Oxagen will map and further refine the regions of association defined by these SNPs to locate disease genes and identify the functional polymorphisms within them

Companies may seek pharmaceutical partners for package; terms ND (5/99)

Magainin Pharmaceuticals Inc.

Genentech Inc.

Collaborative research and option agreement on use of Magainin's asthma functional genomics database (especially interleukin-9; IL-9) for developing protein therapeutic (blocking antibody) for treating asthma

Genentech gets access to IL-9 therapeutic target; companies will explore potential of blocking antibody to IL-9 to suppress asthmatic response; Genentech made initial $2M equity investment in Magainin (10% premium to market); Genentech has option to enter into development and commercialization agreement; if it exercises option, Magainin gets $35M in payments and royalties (1/99)

Medarex Inc.

Immunex Corp.

Licensing agreement on Medarex's HuMAb-Mouse technology to produce fully human monoclonal antibodies to Immunex targets

Immunex gets rights to use technology throughout its organization for an unlimited number of targets for 10 years; Medarex gets technology access fees, license fees, research payments, milestones and royalties (1/99)

Medarex Inc.

LeukoSite Inc.

Expansion of 10/97 licensing agreement on Medarex's HuMAbMouse technology to produce fully human monoclonal antibodies to LeukoSite targets

LeukoSite gets rights to use technology for a number of targets; Medarex gets license fees, milestones and royalties; Medarex also gets certain rights to an anti-interleukin-8 antibody that was jointly developed by LeukoSite and Medarex subsidiary GenPharm (2/99)

Medarex Inc.

Amgen Inc.

Antibody development collaboration in which Medarex will use its HuMAbMouse technology to generate fully human monoclonal antibodies to multiple targets for Amgen

Medarex will receive research and development payments from Amgen, and could receive additional fees and milestone payments, plus royalties on future product sales; Amgen will be responsible for product development, manufacturing and marketing of any products developed through the collaboration (9/99)

Medarex Inc.

Eos Biotechnology Inc.

Antibody development collaboration in which Eos will have access to Medarex's HuMAb-Mouse technology for the generation of fully human antibodies to Eos' genomics-derived immunotherapeutic targets

Medarex could receive research payments, license fees and milestone payments, as well as royalties on therapeutic product sales (8/99)

Medarex Inc.

IDM
(France)

Research collaboration using Medarex's HuMAb-Mouse technology for the generation of fully human antibodies to multiple targets; IDM also becomes Medarex's first partner for CTLA-4 Blockade technology to enhance cancer vaccines; IDM will use the technology with its Dendritophages as a cellular vaccine for melanoma and prostate cancers

Medarex could receive research payments, license fees, milestones, and royalties on any sales (12/99)

Millennium Pharmaceuticals Inc.

Cetek Corp.

Research agreement allowing Millennium to evaluate Cetek's proprietary screening technology in screening genomic target

Cetek will develop assays and screens against compound libraries from Millennium; further details ND (9/99)

Molecular Applications Group

Celera Genomics

Celera purchased Panther technology, a functional genomics software tool, from MAG

Purchase; further terms ND (12/99)

Molecular Biology Resources Inc.

Invitrogen Corp.

Invitrogen acquired sole ownership of the patents that cover technologies used in the TA Cloning method, a polymerase chain reaction technique used in functional genomics research and gene-based drug discovery

Previously, Molecular Biology and Invitrogen were co-owners of the patents; acquisition gives Invitrogen exclusive worldwide royaltyfree rights as the sole assignee through 2013, the life of the patents; financial terms ND (6/99)

MondoGen GmbH
(Germany)

HepaVec AG
(Germany)

HepaVec took a majority stake in MondoGen, thus acquiring access to MondoGen's complementary liver-specific vector technology, based on a modified version of the hepatitis B virus

HepaVec acquired a majority stake in MondoGen; financial details ND (11/99)

MorphoSys AG
(Germany)

Chiron Corp.

License agreement; use of MorphoSys' HuCAL (human combinatorial antibody library) technology for generating human antibodies

2-year agreement; MorphoSys gets licensing fees, milestones and royalties; Chiron has option to renew license for 3 more years; financial terms ND (1/99)

MorphoSys AG
(Germany)

Biosite Diagnostics Inc.

License agreement under which Biosite's collaborative antibody development program, Biosite Discovery, will provide MorphoSys with a non-exclusive license to use phage display of Fab and/or other multichain antibodies to develop antibodies from MorphoSys' HuCAL antibody libraries; Biosite gains access to certain diagnostic markers MorphoSys has generated under partnerships

Companies will pay each other revenues based on the sale of licensed product (12/99)

Nanoscale Combinatorial Synthesis Inc.
(Nanosyn)

Caliper Technologies Inc.

Nanosyn will provide Caliper with custom combinatorial libraries that combine Caliper's microfluidics screening technology with Nanosyn's miniaturized synthesis technology

ND (2/99)

Neogenesis Inc.

Creative BioMolecules Inc.

Research agreement in which Creative BioMolecules will have access to Neogenesis's library of small molecules and screening approaches to advance and accelerate its drug discovery process

ND (7/99)

Neomorphic Software Inc.

SyStemix Inc.
(unit of Novartis AG; Switzerland)

Research collaboration under which Neomorphic's hidden Markov model technology will be used to identify genes in SyStemix's gene sequence database

ND (5/99)

Neurochem Inc.
(Canada)

Resolution Pharmaceuticals Inc.

R&D collaboration to develop radioimaging diagnostic agents targeted at amyloid deposits associated with Alzheimer's disease

The companies will jointly identify and develop products resulting from the combination of Neurochem's amyloid targeting molecules and Resolution's radioimaging platform technology; subsequent development of lead molecules will be carried out by both companies; financial details ND (7/99)

Novavax Inc.

Organogenesis Inc.

Research collaboration; use of Novavax's transdermal drug delivery technology with Organogenesis' tissue engineering technology to develop therapeutics for undisclosed disease targets

ND (1/99)

Novavax Inc.

Cantab Pharmaceuticals plc
(UK)

Cantab exercised option under 1/98 agreement to license Novasomes (liposome adjuvants) for therapeutic vaccination of women with cervical intraepithelial neoplasia, a precancerous condition caused by human papilloma virus infection

Novavax will receive additional license fees and milestones, plus potential royalties (4/99)

Ocean Pharmaceuticals Inc.
(Canada)

Synsorb Biotech Inc.
(Canada)

Research collaboration; screening of Ocean's marine microorganisms as alternate sources for antibiotics for bacterial and fungal infections

Synsorb will provide financial and technical support for product development through preclinical stage, at which point it will acquire rights to compounds and conduct clinical trials (1/99)

Ontogeny Inc.

Biogen Inc.

Extension and expansion of 7/96 agreement on 3 Hedgehog cell differentiation proteins (which induce formation or regeneration of tissues; Sonic, Indian and Desert); covers most disease areas, initially central nervous system disorders

Agreement extended through 6/01 and expanded to include certain areas of gene therapy; financial terms ND (2/99)

Orchid Biocomputer Inc.

Affymetrix Inc.

Development and commercialization agreement for singgle nucleotide polymorphism genotyping assays that combine Orchid's GBA primer extension technology with a new GeneChip array product offering from Affymetrix

Orchid will develop and manufacture GBA primer extension reagent kits that are directed to defined sets of SNPs and that can be customized by the end user; Affymetrix will distribute and manufacture the universal GeneChip arrays, and will provide marketing, sales and technical support; Affymetrix invested in Orchid's 1/00 financing as part of the deal (12/99)

OSI Pharmaceuticals Inc.

BioChem Pharma Inc.
(Canada)

License agreement replacing earlier collaborative program focused on antiviral drug discovery; OSI is licensing to BioChem rights to the companies' joint technology in certain antiviral targets

OSI will receive a $2M up-front licensing fee, plus milestones and royalties; companies have crosslicensed joint technology in HIV, allowing both to continue R&D in this area (3/99)

Oxford Asymmetry International plc
(UK)

Ontogeny Inc.

Optimization agreement on smallmolecule leads derived from Ontogeny's developmental pathwaybased assays

Oxford Asymmetry will provide Ontogeny with medicinal chemistry service, and will give Ontogeny access to its combinatorial chemistry expertise; financial terms ND (6/99)

Oxford
Biomedica plc
(UK)

ViroMed Ltd.
(Korea)

Joint venture agreement for Southeast Asia markets; deal establishes Virotech Ltd. to combine Oxford's lentiviral vector and enzyme/prodrug technologies with ViroMed's vector development technology, clinical trial facilities and development expertise

ND (5/99)

OXIS International
(France)

ND

OXIS assigned rights to its patents related to polyalkalene glycols (PEG) to an undisclosed party; OXIS will retain a non-exclusive perpetual paid-up license to these patents for PEG conjugated superoxide dismutase

OXIS received an up-front cash payment of $0.6M and will receive an additional $0.23M upon FDA approval of the first U.S. product covered by these patents; OXIS also will receive royalties on any products (11/99)

Pangea Systems Inc.

Genetics Institute Inc.
(wholly owned subsidiary of American Home Products Corp.)

Licensing agreement on Pangea's computational tools for use in Genetics Institute's genomicsbased drug discovery program; tools allow clustering and alignment of expressed sequence tags and full-length genetic sequences

ND (1/99)

Pangea Systems Inc.

Rigel Inc.

Licensing agreement for Pangea's GeneWorld, automated, highthroughput analysis software that allows researchers to access, annotate and analyze genetic sequence data

ND (6/99)

Pangea Systems Inc.

Ontogeny Inc.

Licensing agreement for Pangea's GeneWorld, an automated, highthroughput analysis software that allows researchers to access, annotate and analyze genetic sequence data

ND (6/99)

Pangea Systems Inc.

EOS Technology Inc.

License agreement for Pangea's software for clustering and aligning high volumes of expressed sequence tags and partial gene sequences into full-length gene sequences suitable for gene indexing and other drug-discovery applications

ND (6/99)

Pangea Systems Inc.

Axys Pharmaceuticals Inc.

License agreement for Pangea's software for clustering and aligning high volumes of expressed sequence tags and partial gene sequences into full-length gene sequences suitable for gene indexing and other drug-discovery applications

ND (6/99)

Pangea
Systems Inc.

Genencor International Inc.

Genencor purchased Pangea data on metabolic pathways for an ND organism in order to optimize quality and yield of proteins it manufactures using that organism

ND (6/99)

Pangea
Systems Inc.

Sugen Inc.
(wholly owned subsidiary of Pharmacia & Upjohn)

SUGEN licensed Pangea's Clustering and Alignment Tools, which enable companies to cluster and align high volumes of expressed sequence tags and partial gene sequences into full-length gene sequences

Financial terms ND (11/99)

Pentose Pharmaceuticals Inc.

V.I. Technologies Inc.
(VITEX)

Development, manufacturing and license agreement to combine technologies to enhance viral elimination from pooled transfusion plasma products; the collaboration will focus on applying Pentose's Inactine antiviral technology to VITEX's PLAS+SD plasma prod uct as a second inactivation step that will broaden the spectrum of viral elimination to include non-enveloped viruses

Dependent on the successful achievement of certain milestones, Pentose could receive up to $12M in up-front cash, equity and milestone payments, plus royalties on any future sales; VITEX will obtain exclusive rights in North America and, contingent on certain ND events, non-exclusive rights in the rest of the world to use Inactine in combination with solvent detergent for treating pooled transfusion plasma (3/99)

Pharma Pacific Pty. Ltd.
(Australia; subsidiary of Fernz Corp.)

Coulter Pharmaceutical Inc.

License agreement giving Coulter worldwide rights to Pharma Pacific's 64G12, a therapeutic monoclonal antibody specific for the Type I interferon receptor, which may represent a new approach to the treatment of autoimmune diseases and transplant rejection

Coulter will receive exclusive worldwide rights for all human therapeutic and prophylactic uses for 64G12 and related intellectual property, as well as other antibodies recognizing the Type I interferon receptor; Coulter will be responsible for worldwide clinical development, manufacturing and commercialization; Coulter will pay Pharma Pacific an upfront payment of $1.5M and potential license fees and milestone payments of up to $10.25M; Pharma Pacific will receive royalties on future product sales (6/99)

Pharmacopeia Inc.

Tularik Inc.

R&D agreement for discovery of small-molecule therapeutics; Tularik will provide high-throughput screening technologies, and Pharmacopeia will contribute combinatorial chemistry libraries; Tularik will be responsible for development and commercialization of any products

Pharmacopeia receives an upfront fee, milestones and royalties (4/99)

Pharming N.V.
(the Netherlands)

Genzyme Transgenics Corp.

Genzyme Transgenics gains non-exclusive license to bovine transgenic technology for use in producing human serum albumin in the milk of cattle

Genzyme Transgenics will pay $0.75M up front, a yearly maintenance fee, milestones and royalties on any products (10/99)

Phylos Inc.

Cubist Pharmaceuticals Inc.

Collaboration agreement using Phylos' Profusion technology for the identification of peptide-like agents that bind with high affinity to protein targets

The agents identified in the collaboration will be incorporated into Cubist's VITA (Validation In Vivo for Targets and Assays for Anti-infectives) technology and for the development of high-throughput screening assays; Phylos will receive research funding and, if applicable, milestone payments during the term of the agreement (10/99)

Polymasc Pharmaceuticals plc
(UK)

Onyx Pharmaceuticals Inc.

License agreement executed following successful research collaboration; Onyx will license Polymasc's ViraMASC technology for further development of its genetically modified adenoviruses

Deal triggers a milestone for Polymasc; further milestones and royalties are payable on each product developed (5/99)

PPL Therapeutics plc
(UK)

ND biotechnology company based in the U.S.

Feasibility study for the production of a host-defense peptide in the milk of transgenic rabbits for potential use as an antibiotic

ND (4/99)

Praecis Pharmaceuticals Inc.

Amgen Inc.

Collaboration on Praecis' drug Abarelix (synthetically modified peptide that acts as gonadotropin releasing hormone antagonist) for treating hormonally responsive prostate cancer (currently in Phase III trials) and endometriosis (currently in Phase I/II trials)

Praecis responsible for clinical trials and regulatory approval for prostate cancer indication; Praecis will fund clincial trials in 1999 for endometriosis indication; Amgen will commercialize product in U.S., Canada, Australia, Asia and other markets; Amgen will conduct trials for approvals in non-U.S. territories; Amgen will spend $100M on this collaboration in 1999 (3/99)

ProdiGene Inc.

Genencor International Inc.

Expansion of 10/97 collaboration to develop enzyme products utilizing transgenic plants; alliance combines ProdiGene's expertise in producing recombinant proteins in transgenic plants with Genencor's enzyme technologies

Genencor exercised option to expand alliance and will fund R&D of additional products, plus additional ND consideration (3/99)

Progenitor Inc.

Megabios Inc.

Megabios acquired rights and intellectual property related to the del-1 gene and protein from Progenitor

Megabios made a 1-time cash payment to Progenitor and has milestone and royalty obligations to Vanderbilt University, co-owner of del-1 (4/99)

Prometic Biosciences Inc.
(a subsidiary of Prometic Life Sciences Inc.; Canada)

PowderJect Pharmaceuticals plc (UK)

Collaboration agreement combining Prometic's particle technology with PowderJect's needle-free delivery system

PowderJect will receive a global license to use Prometic's technology in the development and commercialization of pharmaceutical compounds for administration via PowderJect's needle-free delivery system; Prometic will receive collaboration fees and manufacturing rights (9/99)

Protein Design Labs Inc.

Medarex Inc.

Licenses under Protein Design's antibody humanization patents for two of Medarex's bispecific antibodies (not identified) that are now in clinical trials

Medarex gets two nonexclusive worldwide licenses; Protein Design gets signing and licensing fees, annual maintenance fees, milestones and royalties (1/99)

Protein Design Labs Inc.

Progenics Pharmaceuticals Inc.

Licensing agreement to apply PDL's humanization technology to Progenics' PRO 140, an anti-CCR5 monoclonal antibody that blocks HIV replication and is slated to enter clinical trials in 2000

Progenics will pay a licensing and signing fee, plus milestones and royalties on any sales (5/99)

Protein Design Labs Inc.

BioNet Pharma GmbH
(Germany)

Development and marketing agreement for PDL's SMART (humanized) Anti-L-Selectin Antibody in Europe, the Middle East and Africa

PDL receives $3M licensing fee and will be entitled to royalties on any sales; PDL will pay milestones to BioNet for meeting clinical and regulatory goals (5/99)

Sangamo Biosciences Inc.

Genset SA
(France)

Research agreement; Sangamo will provide specific Universal GeneTools to Genset for use in its target validation programs

ND (9/99)

Sangamo Biosciences Inc.

Immunex Corp.

Research agreement; Sangamo will provide specific Universal GeneTools to Immunex for use in its internal research and validation programs

ND (9/99)

Scios Inc.

Chiron Corp.

Chiron gains a license to Scios' rights to human basic fibroblast growth factor, a stimulator of blood vessel formation and other tissue repair processes

Chiron will pay licensing fees of $12.5M in the form of cash and a forgivable loan; in addition, Scios could receive milestones of $12M, plus royalties on any sales (12/99)

Signal Pharmaceuticals Inc.

Axys Pharmaceuticals Inc.

Axys gains exclusive, world wide development and marketing rights to Signal's selective estrogen receptor-beta modulators (SERM-beta) for the treatment of cancer

Signal will receive a license fee, research funding, milestones and royalties; Signal may exercise a profitand cost-sharing option in the U.S. at a predeter mined point in lieu of royalties on product sales (10/99)

Selective Genetics

Biomet Inc.

Licensing agreement covers Selective Genetics' Gene Activated Matrix and and other technologies for orthopedic indications; initial studies, planned for late 1999 or early 2000, are expected to address fracture repair in elderly osteoporotic patients

Selective Genetics could receive in excess of $32M, consisting of an upfront equity investment of $5M, R&D funding over a 10-year period and a potential further equity investment; Selective will also receive a royalty on net product sales (5/99)

Sequenom Inc.

Genzyme Genetics
(a unit of Genzyme Corp.)

License agreement for the development of mutation detection assays using Sequenom's MassArray and SpectroChips technologies

ND (9/99)

Sequitur Inc.

Genome Therapeutics Corp.

Expansion of research collaboration; Genome receives non-exclusive access to Sequitur's antisense functional genomics technology and to high-specificity antisense compounds, cellular delivery compounds and proprietary computer target site selection technology

ND (9/99)

Small Molecule Therapeutics Inc.

Hybrigenics SA
(France)

Small Molecule will screen Hybrigenics infectious disease targets derived from protein interaction maps; lead compounds will be further validated in Hybrigenics' modeling systems

Companies will partner any potential drugs arising from collaboration with pharmaceutical partners; further details ND (3/99)

Strata Biosciences Inc.

Tularik Inc.

Research collaboration on highthroughput target validation; use of Strata's functional genomics technology in Tularik's drug discovery program

2-year collaboration; Strata will get funding from Tularik as well as milestone payments (2/99)

Structural Bioinformatics Inc.

BioChem Pharma Inc.
(Canada)

Research collaboration for generating and optimizing lead compounds for the treatment of a ND viral infectious disease

Structural Bioinformatics will work with BioChem scientists using its proprietary protein modeling, DynaPharm and CombiLib technologies; BioChem will expand its financial commitments, which encompass research funding and milestone and royalty payments (7/99)

Synsorb Biotech Inc.
(Canada)

BCY Ventures Inc.

Sublicensing agreement for preclin ical cystic fibrosis therapies Synsorb licensed from a consortium of Novadex Pharmaceuticals and various Canadian academic institutions

BCY gains exclusive license and will assume all financial responsibility in exchange for 2M shares of BCY stock, representing 37% of the company on a fully diluted basis; Synsorb retains option to manufacture product (6/99)

Systems Integration Drug Discov ery Co. Inc.

CellPath Inc.

Shared-risk drug discovery collaboration; SIDDCO will synthesize compounds for hit generation and lead optimization via combinatorial chemistry; CellPath will test compounds in its screens that use cancer cells freshly isolated from patients

ND (2/99)

Targeted Genetics Corp.

Sangamo BioSciences Inc.

Licensing agreement; use of Targeted Genetics' gene delivery vectors (adeno-associated, retroviral and nonviral cationic lipid) to enhance Sangamo's Universal GeneTools technology (to combine gene transfer and gene regulation in single product)

Sangamo gets nonexclusive license to Targeted Genetics' vectors; Targeted Genetics gets royalties on sales of enhanced product (1/99)

Telik Inc.

Cor Therapeutics Inc.

Research collaboration; use of Telik's TRAP chemoinformatics drug discovery technology to screen compounds against up to 5 disease targets (undisclosed) selected by Cor

Cor gets rights to any products worldwide except in Asia; Telik gets license fee, milestones and royalties; Telik retains rights in Asia, which it may reassign to 3rd party; financial terms ND (1/99)

Telik Inc.

Scios Inc.

Drug screening and license agreement; use of Telik's TRAP chemoinformatics drug discovery technology and diverse compound library to identify small molecules with affinity for Scios' target (not identified)

Scios gets rights to any products worldwide except in Asia; Telik gets license fee, milestones and royalties; Telik retains rights in Asia, which it may reassign to 3rd party; financial terms ND (2/99)

Trega Biosciences Inc.

Isis Pharmaceuticals Inc.

Isis will purchase combinatorial libraries from Trega through its Chem.Folio program

Isis gets nonexclusive access to Trega's small-molecule combinatorial libraries in exchange for up-front payment on each compound delivered; Isis has option to license synthetic protocols for libraries from which active compounds are identified; specific terms ND (3/99)

Tripos Inc.

Cyprotex
(division of Medeval Ltd.; UK)

Technology collaboration; enhancement of design of chemical libraries using in vitro pharmacokinetic profiling and the prediction of in vivo drug absorption, distribution, metabolism and excretion

Financial terms ND (11/99)

Vaxcel Inc.

Innovax Corp.
(joint venture of Endorex Corp. and Elan Corp. plc [Ireland])

License agreement for Vaxcel's technology and patents for orally delivered human and veterinary vac cines based on polymeric microspheres

ND (5/99)

Vion Pharmaceuticals Inc.

EPTTCO Ltd.
(UK)

R&D collaboration to develop cancer treatments by combining Vion's TAPET bacterial vectors with EPTTCO's prodrug activation technology, which uses enzymes to convert inactive prodrugs into cytotoxic anticancer agents

Both parties will equally contribute technology and manpower to establish and test the combined therapeutic system; if a specific combi nation proves successful, the collaboration will seek a corporate partner to clinically develop and commercialize the product (4/99)

Xenometrix Inc.

GeneTrace Systems Inc.

License agreement on Xenometrix's gene expression profiling; covers collection of gene expression profiles using all methods, including highdensity microarrays

GeneTrace gets nonexclusive license; further details ND (2/99)

Xenometrix Inc.

Genzyme Molecular Oncology

License agreement on Xenometrix's gene expression profiling; covers collection of gene expression profiles using all methods, including highdensity microarrays

Genzyme Molecular gets nonexclusive license; further details ND (2/99)

Xenometrix Inc.

Incyte Pharmaceuticals Inc.

License agreement on Xenometrix's gene expression profiling; covers collection of gene expression profiles using all methods, including highdensity microarrays

Incyte gets non-exclusive license; further details ND (2/99)

Xoma Ltd.

Biosite Diagnostics Inc.

Licensing agreement on Xoma's bacterial cell expression system for producing and manufacturing genetically engineered diagnostic antibodies; separate licensing agreement on Xoma's patents for phage display selection of antibodyrelated protein products

Biosite gets non-exclusive licenses to Xoma's technologies and will pay upfront fees, milestones and royalties (1/99)

Xoma Ltd.

Genentech Inc.

Licensing agreement on Xoma's bacterial cell expression system for producing and manufacturing genetically engineered therapeutic and diagnostic antibodies

Xoma cross-licensed Genentech's antibody-related cell expression patents; Genentech gets non-exclusive license to Xoma's technology and will pay upfront fees, milestones and royalties (1/99)

Xoma Ltd.

Allergan Inc.

Licensing agreement under which Allergan gains rights to use Xoma's recombinant bactericidal/permeability increasing protein (rBPI) in combination with other anti-infectives to treat ophthalmic infections

Xoma will receive up to $11M, consisting of up-front payment and milestones, plus royalties on any Allergan products using rBPI; Allergan will pay all future development costs of covered products; a Xoma affiliate will manufacture rBPI for Allergan (6/99)

Xoma Ltd.

Genentech Inc.

Expansion of 4/96 hu1124 antibody product development program to include organ transplant rejection

ND (8/99)


Back to Top

No Comments
BioWorld MedTech